Aclarion (ACON) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
A special meeting of stockholders is scheduled for September 2024 to vote on a reverse stock split proposal, with the board recommending approval.
The reverse stock split would allow the board to combine outstanding shares at a ratio between 1-for-5 and 1-for-50, to be determined at the board's discretion within one year of approval.
The primary goal is to increase the per-share price to regain compliance with Nasdaq's minimum bid price requirement and attract a broader investor base.
If approved, the board may implement or abandon the split at its discretion, considering market and company conditions.
Voting matters and shareholder proposals
The sole proposal is to grant the board authority to amend the certificate of incorporation for a reverse stock split within a specified ratio range.
Approval requires a majority of votes cast; abstentions and broker non-votes have no effect.
Brokers may exercise discretion to vote uninstructed shares on this routine matter.
No appraisal rights are available to stockholders for this proposal.
Board of directors and corporate governance
The board unanimously recommends voting in favor of the reverse stock split proposal.
Proxies are solicited by the board, with Brent Ness and Jeffrey Thramann designated as proxies.
The board may abandon the reverse stock split even after stockholder approval if deemed not in the best interest of the company.
Latest events from Aclarion
- Revenue up 65.6% to $75.7K; net loss $7.2M; $22.6M raised in 2025, $10.4M in 2026.ACON
Q4 202518 Mar 2026 - Non-invasive spinal diagnostics see clinical, commercial, and reimbursement momentum in key markets.ACON
Investor Update23 Jan 2026 - Non-invasive lumbar disc diagnostics show strong outcomes and payer traction, driving expansion.ACON
Investor Update12 Jan 2026 - Shelf registration enables up to $50M in offerings for AI-driven spine diagnostics in a high-need market.ACON
Registration Filing16 Dec 2025 - Healthcare tech firm targets $50M raise amid Nasdaq risks, leveraging patented MRS diagnostics.ACON
Registration Filing16 Dec 2025 - AI-driven diagnostics firm faces Nasdaq risks, offers 27.5M shares for resale, no direct proceeds.ACON
Registration Filing16 Dec 2025 - Up to $150M in securities to fund AI-driven diagnostics for back and neck pain; high risk, high potential.ACON
Registration Filing16 Dec 2025 - Key votes include director elections, auditor ratification, a reverse split, and equity plan changes.ACON
Proxy Filing2 Dec 2025 - Key votes include director elections, auditor ratification, share issuances, and a reverse stock split.ACON
Proxy Filing2 Dec 2025